Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PP2Cα CRISPR/Cas9 KO Plasmid (m): sc-422374
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PP2Cα CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PP2Cα genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PP2Cα Antibody (7F12): sc-517264
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PP2Cα CRISPR/Cas9 KO Plasmid (m) | sc-422374 | 20 µg | $397.00 |
Overview
Ppm1a encodes protein phosphatase 2C alpha (PP2Cα), a Mg2+/Mn2+-dependent serine/threonine phosphatase that functions as a negative regulator of stress-activated signaling. PP2Cα modulates MAPK pathways, including p38 and JNK cascades, by dephosphorylating key kinases and shaping downstream transcriptional programs that govern inflammation, apoptosis, and cell-cycle control. It also intersects with DNA damage and metabolic stress responses, helping tune signal duration and amplitude in response to environmental cues. Dysregulated PP2Cα activity has been associated with aberrant stress signaling and oncogenic phenotypes, supporting its study in tumor biology, immune regulation, and cellular homeostasis.
PP2Cα CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ppm1a gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ppm1a together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ppm1a open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PP2Cα protein expression.
This CRISPR knockout system enables efficient generation of Ppm1a-deficient cell models for investigation of PP2Cα signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Ppm1a exon(s) critical for PP2Cα function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Ppm1a genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PP2Cα CRISPR/Cas9 KO Plasmid (m) and PP2Cα CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Ppm1a locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PP2Cα HDR Plasmid (m) and PP2Cα HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Ppm1a homology arms to support homology-directed repair at defined Ppm1a target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.